France-based Erytech Pharma SA has nominated Luc Dochez as an independent member of its board of directors. Mr Dochez was most recently chief business officer at Prosensa Holding NV, an RNA-therapeutics company that was acquired by BioMarin Pharmaceutical Inc in January. Before joining Prosensa he was a consultant within Arthur D Little’s biotechnology practice.
Mr Dochez holds a Doctor of Pharmacy degree from the University of Leuven and an MBA degree from Vlerick Management School.
Erytech announced the appointment on 26 March 2015.
Copyright 2015 Evernow Publishing Ltd